Fischer Imaging completes $4 M stock sale

Article

Fischer Imaging announced that it has completed a private placement of one million shares of its common stock to entities controlled by Deerfield Management. The shares were sold at $4 each—a 56% premium on the company’s closing stock price of

Fischer Imaging announced that it has completed a private placement of one million shares of its common stock to entities controlled by Deerfield Management. The shares were sold at $4 each—a 56% premium on the company’s closing stock price of $2.56—on Friday, Aug. 25.

“Having been stockholders of Fischer Imaging for a number of years, we are encouraged that operationally the company has turned the corner and is ready to reap the benefits of its investment in digital mammography and other new technologies,” said Arnold Snider, general partner of Deerfield.

Fischer Imaging’s revenue was down (SCAN 5/24/00) as it prepared an FDA submission for its SenoScan full-field digital mammography system.

“This investment provides Fischer with additional financial flexibility as we prepare to launch our SenoScan full-field digital mammography system later this year,” said Morgan W. Nields, chairman and CEO of Fischer.

“The company’s balance sheet has improved significantly over the last 12 months as Fischer completed its exit from the OEM business,” said Rod Johnson, Fischer’s chief financial officer.

Revenue decreased 3% to $13.7 million for the first quarter of 2000 (end April 2) compared to $14.2 million for the first quarter of 1999. These figures do not include the sale of a $6.2-million technology license to GE Medical.

The deal with GE involves a Fischer design for a C-arm attachment for cardiology equipment. The license agreement says GE can manufacture the C-arm itself or outsource it to another company.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.